Related Experiment Video
Updated: Feb 13, 2026
Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy
Published on: April 29, 2014
A national, multicenter, non-interventional, observational study on treatment patterns in patients with metastatic
Şuayib Yalçın1, Ramazan Yildiz2, Faysal Dane3
1Hacettepe University, Department of Medical Oncology, Ankara, Turkey.
Introduction:
The introduction of targeted therapies in renal cell carcinoma has significantly improved its prognosis and treatment outcomes in recent years. Such treatment options are targeted therapies of the vascular endothelial growth factor (VEGF) pathway and the mammalian target of the rapamycin pathway. With the use of tyrosine kinase inhibitors (TKIs) and mammalian target of the rapamycin inhibitors, overall survival has increased up to 2 years. In Turkey, due to applicable reimbursement conditions for patients with metastatic renal cell carcinoma (mRCC), interferon use is mandated as a first-line treatment, thus providing information on the use of everolimus only after initial interferon and second-line VEGF-targeted treatments such as VEGF-TKI.
Patients And Methods:
To provide a first real-life data set in Turkey, we conducted a prospective, non-interventional, observational study and assessed the efficacy and safety of everolimus after two lines of treatment including interferon. A total of 100 patients with histologically confirmed mRCC were enrolled in the study from 11 centers between June 2012 and March 2014 (70 males and 30 females). Efficacy was assessed on the basis of progression-free survival and overall survival; safety of everolimus was assessed on the basis of adverse event occurrence.
Results:
The study results showed that the median progression-free survival with everolimus treatment was 8.1 months (95% CI: 5.1-11.1) and the median overall survival was 17.6 months (95% CI: 10.1-25.1), thus indicating a better overall response based on survival durations than those from the randomized Phase III REnal Cell cancer treatment with Oral RAD001 given Daily study results (4.9 and 14.8 months, respectively).
Conclusion:
The study showed that everolimus treatment is a safe and effective treatment option in the treatment of mRCC after VEGF-TKI, with an acceptable safety and tolerability profile in real-life settings.
Insights
Everolimus offers a safe and effective treatment for metastatic renal cell carcinoma (mRCC) after initial therapies. Real-world data shows improved progression-free and overall survival compared to previous studies.
Area of Science:
- Oncology
- Pharmacology
- Clinical Research
Background:
- Targeted therapies, including VEGF and mTOR pathway inhibitors, have improved renal cell carcinoma outcomes.
- In Turkey, reimbursement policies mandate interferon and VEGF-TKI use before other treatments for metastatic renal cell carcinoma (mRCC).
Purpose of the Study:
- To evaluate the efficacy and safety of everolimus in Turkish patients with mRCC.
- To provide real-world data on everolimus use after two prior treatment lines (interferon and VEGF-TKI).
Main Methods:
- Prospective, non-interventional, observational study involving 100 mRCC patients across 11 centers.
- Assessed progression-free survival, overall survival, and adverse events associated with everolimus treatment.
Main Results:
- Median progression-free survival was 8.1 months (95% CI: 5.1-11.1).
- Median overall survival was 17.6 months (95% CI: 10.1-25.1).
- Survival outcomes exceeded those reported in the RAD001 Phase III trial.
Conclusions:
- Everolimus demonstrates a safe and effective treatment option for mRCC in real-world settings.
- The drug exhibits an acceptable safety and tolerability profile for patients previously treated with VEGF-TKI.
More Related Videos
05:36Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane
Published on: February 8, 2020
06:38A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
Related Concept Videos
01:11Observational Studies
There are three types of observational studies – Prospective, retrospective, and cross-sectional.
Prospective Study
Prospective studies, also known as longitudinal or cohort studies, are carried out by collecting future data from groups sharing similar characteristics. One...
01:24Serum Studies: Renal Function Tests
01:15Bioavailability Study Design: Healthy Subjects Versus Patients
01:22Case Studies
01:26National Nursing Organizations I
01:30National Nursing Organizations II
The AACN emphasizes a healthy work environment through six standards to achieve an optimal patient outcome. The standards are appropriate staffing, meaningful recognition, collaboration, authentic leadership, effective communication, and decision-making. In addition, AACN provides certification programs, webinars, journals, and...